Intel
INTC
Oracle
ORCL
Netflix
NFLX
4
Meta Platforms
META
5
Apple
AAPL
US Stock MarketDetailed Quotes
CYCC Cyclacel Pharmaceuticals
- 0.2853
- +0.0068+2.44%
Close Apr 28 16:00 ET
- 0.2311
- -0.0542-19.00%
Pre 07:28 ET
59.15MMarket Cap-0.14P/E (TTM)
0.4198High0.2500Low10.98MVolume0.2986Open0.2785Pre Close3.72MTurnover86.41%Turnover RatioLossP/E (Static)207.34MShares3.083552wk High-28.53P/B3.63MFloat Cap0.170652wk Low--Dividend TTM12.71MShs Float2141994.0840Historical High--Div YieldTTM60.97%Amplitude0.1706Historical Low0.3380Avg Price1Lot Size
Cyclacel Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 50.41%-7.99M | 65.32%-1.36M | 24.01%-3.07M | -136.32%-3.08M | 92.96%-483K | 22.64%-16.11M | 24.36%-3.91M | 42.08%-4.04M | 31.85%-1.31M | -1.27%-6.86M |
| Net income from continuing operations | 50.29%-11.21M | 42.10%-3.05M | 67.56%-1.96M | 40.22%-3.26M | 49.24%-2.95M | -6.40%-22.56M | 28.95%-5.27M | -18.37%-6.03M | -19.08%-5.45M | -41.29%-5.8M |
| Depreciation and amortization | -80.65%6K | -87.50%1K | -85.71%1K | -75.00%2K | -75.00%2K | -3.13%31K | 0.00%8K | 0.00%7K | 0.00%8K | -11.11%8K |
| Other non cash items | ---- | ---- | 66.67%-5K | -14.29%-16K | 38.46%-16K | ---- | ---- | ---15K | ---14K | -73.33%-26K |
| Change In working capital | -46.87%2.62M | 60.35%1.57M | -175.20%-1.21M | -100.05%-2K | 257.92%2.27M | 523.22%4.94M | -47.39%976K | 171.12%1.61M | 65.72%3.79M | 52.65%-1.44M |
| -Change in prepaid assets | -5.09%4.47M | -0.37%1.34M | -189.33%-67K | -74.00%1.18M | 263.70%2.02M | 224.52%4.71M | 239.26%1.35M | 103.97%75K | 41.34%4.52M | 70.09%-1.23M |
| -Change in payables and accrued expense | -711.82%-1.81M | 185.48%259K | -174.51%-1.15M | -60.71%-1.18M | 223.30%254K | -88.51%296K | -110.78%-303K | 477.89%1.54M | 19.72%-733K | -118.99%-206K |
| -Change in other current liabilities | 46.38%-37K | ---- | ---- | ---- | ---- | -272.50%-69K | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 50.41%-7.99M | 65.32%-1.36M | 24.01%-3.07M | -136.32%-3.08M | 92.96%-483K | 22.64%-16.11M | 24.36%-3.91M | 42.08%-4.04M | 31.85%-1.31M | -1.27%-6.86M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 0 | 0 | 0 | 14.29%-6K | 0 | 0 | 0 | -50.00%-6K |
| Net PPE purchase and sale | --0 | --0 | --0 | --0 | --0 | 14.29%-6K | --0 | --0 | --0 | -50.00%-6K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | --0 | --0 | --0 | 14.29%-6K | --0 | --0 | --0 | -50.00%-6K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 822.41%7.82M | 61.46%1.61M | 98.00%-1K | 12,431.37%6.29M | -58.00%-79K | -71.71%848K | 2,278.57%999K | -103.26%-50K | -103.46%-51K | 0.00%-50K |
| Net common stock issuance | 491.90%6.21M | --0 | ---1K | ---- | ---- | -67.21%1.05M | 1,040.22%1.05M | --0 | ---- | ---- |
| Cash dividends paid | --0 | --0 | --0 | --0 | --0 | 0.00%-201K | 0.00%-50K | 0.00%-50K | 0.00%-51K | 0.00%-50K |
| Proceeds from stock option exercised by employees | --1.61M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net other financing activities | ---- | ---- | ---- | ---- | ---79K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 822.41%7.82M | 61.46%1.61M | 98.00%-1K | 12,431.37%6.29M | -58.00%-79K | -71.71%848K | 2,278.57%999K | -103.26%-50K | -103.46%-51K | 0.00%-50K |
| Net cash flow | ||||||||||
| Beginning cash position | -81.59%3.38M | -49.83%2.98M | -40.97%6M | -75.53%2.8M | -81.59%3.38M | -49.82%18.35M | -74.93%5.94M | -65.04%10.16M | -61.42%11.44M | -49.82%18.35M |
| Current changes in cash | 98.90%-168K | 108.83%257K | 24.91%-3.07M | 336.36%3.21M | 91.88%-562K | 14.39%-15.27M | 43.22%-2.91M | 24.83%-4.09M | -205.41%-1.36M | -1.29%-6.92M |
| Effect of exchange rate changes | -124.09%-73K | -129.57%-102K | 137.31%50K | -103.53%-3K | -357.14%-18K | 180.16%303K | 247.44%345K | -306.15%-134K | 172.03%85K | 107.69%7K |
| End cash Position | -7.13%3.14M | -7.13%3.14M | -49.83%2.98M | -40.97%6M | -75.53%2.8M | -81.59%3.38M | -81.59%3.38M | -74.93%5.94M | -65.04%10.16M | -61.42%11.44M |
| Free cash flow | 50.43%-7.99M | 65.32%-1.36M | 24.01%-3.07M | -136.32%-3.08M | 92.97%-483K | 22.64%-16.12M | 24.36%-3.91M | 42.08%-4.04M | 31.96%-1.31M | -1.30%-6.87M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call